Skip to main content

Peramivir Side Effects

Medically reviewed by Drugs.com. Last updated on May 19, 2024.

Applies to peramivir: intravenous solution, solution iv (infusion).

Serious side effects of peramivir

Along with its needed effects, peramivir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking peramivir:

Less common

  • cloudy urine
  • fever

Incidence not known

  • blistering, peeling, or loosening of the skin
  • chills
  • confusion as to time, place, or person
  • cough
  • cracks in the skin
  • diarrhea
  • difficulty swallowing
  • dizziness
  • fast heartbeat
  • hives, itching, skin rash
  • holding false beliefs that cannot be changed by fact
  • joint or muscle pain
  • loss of heat from the body
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red, irritated eyes
  • red, swollen skin
  • red skin lesions, often with a purple center
  • scaly skin
  • seeing, hearing, or feeling things that are not there
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • tightness in the chest
  • trouble breathing
  • unusual excitement, nervousness, or restlessness
  • unusual tiredness or weakness

Other side effects of peramivir

Some side effects of peramivir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • blurred vision
  • constipation
  • difficulty having a bowel movement
  • headache
  • nervousness
  • pounding in the ears
  • redness of the eardrum
  • slow or fast heartbeat
  • trouble sleeping
  • vomiting

For healthcare professionals

Applies to peramivir: intravenous solution.

Hematologic

Decreased neutrophil count (less than 1 x 10[9]/L) was reported in 8% of patients.[Ref]

Gastrointestinal

Vomiting was reported in 3% of pediatric patients; this side effect was not reported in adults.[Ref]

Metabolic

Elevated serum glucose (greater than 160 mg/dL) was reported in 5% of patients.[Ref]

Musculoskeletal

Elevated creatine phosphokinase (at least 6 times the upper limit of normal [6 x ULN]) was reported in 4% of patients.[Ref]

Hepatic

Increased ALT (greater than 2.5 x ULN) was reported in 3% of patients.

Elevated liver enzymes have been reported in healthy subjects and patients with influenza-like illness using this drug.[Ref]

Psychiatric

Delirium and abnormal behavior leading to injury have been reported during postmarketing experience in influenza patients using this drug. These side effects were primarily reported in pediatric patients, often with abrupt onset and rapid resolution; the contribution of this drug to such events has not been established.[Ref]

Cardiovascular

Dermatologic

Other

Fever and tympanic membrane erythema were reported in 2% (each) of pediatric patients; these side effects were not reported in adults.[Ref]

Hypersensitivity

Genitourinary

Proteinuria (by dipstick analysis) was reported in 3% of pediatric patients; this side effect was not reported in adults.[Ref]

Renal

Nervous system

Ocular

Local

References

1. (2015) "Product Information. Rapivab (peramivir)." BioCryst Pharmaceuticals Inc

2. EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid

Further information

Peramivir side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.